文献速递神经肿瘤神经重症

新辅助伽玛刀治疗脑转移瘤对软脑膜播散的影响

Neoadjuvant gamma knife surgery for metastatic brain tumor: clinical use and impact on leptomeningeal seeding.
PubMed 文献 · J Neurooncol · 2025-11-28

本研究回顾性分析2008至2022年单中心120例脑转移瘤患者,比较新辅助与辅助伽玛刀手术(GKS)的软脑膜播散(LMS)发生率、局部失败率及生存结局。两组总生存(p=0.21)、无进展生存(p=0.27)、放射性水肿(p=0.219)及局部失败(p=0.19)无显著差异,但新辅助组LMS发生率显著更低(p=0.043),倾向性评分匹配后优势仍维持(p=0.046)。结论提示新辅助GKS在生存和局部控制上与辅助GKS相当,且显著降低LMS风险。

要点

  • 新辅助GKS与辅助GKS在OS、PFS、局部失败及放射性水肿上无显著差异。
  • 新辅助GKS组LMS发生率显著低于辅助组(p=0.043),匹配后仍显著(p=0.046)。
  • 研究支持新辅助GKS在脑转移瘤管理中可能具有临床优势。

核心结论

  • 新辅助GKS在脑转移瘤患者中生存和局部失败结局与辅助GKS相当,且显著降低LMS风险。

主要发现

  • 两组OS无显著差异(p=0.21),PFS无显著差异(p=0.27)。
  • 两组放射性水肿无显著差异(p=0.219),局部失败无显著差异(p=0.19)。
  • 新辅助组LMS发生率显著更低(p=0.043),倾向性评分匹配后仍显著(p=0.046)。
  • 两组在原发肿瘤来源、术前KPS及颅外转移方面基线差异有统计学意义。

临床怎么用

  • 在脑转移瘤的GKS治疗决策中,可考虑新辅助策略以降低LMS风险,同时不牺牲生存和局部控制。

局限性

  • 本研究为单中心回顾性分析,基线特征存在显著差异,可能影响结果解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study aimed to compare leptomeningeal seeding (LMS) incidence, local failure rates, and survival outcomes between neoadjuvant and adjuvant gamma knife surgery (GKS) in patients with brain metastases. METHODS: We retrospectively analyzed 120 patients treated at a single institution from 2008 to 2022. Overall survival (OS), progression‑free survival (PFS), LMS occurrence, local failure, and key clinical prognostic variables were compared between the neoadjuvant and adjuvant GKS groups. RESULTS: Seventy patients received neoadjuvant GKS, while 50 received adjuvant GKS. Baseline differences in primary tumor origin, preoperative Karnofsky Performance Score, and extracranial metastasis were statistically significant. No significant differences were observed in OS (p = 0.21), PFS (p = 0.27), radiation induced edema (p = 0.219) or local failure (p = 0.19) between groups. LMS incidence was significantly lower in the neoadjuvant group (p = 0.043), with this advantage maintained after propensity score matching (p = 0.046). CONCLUSIONS: Neoadjuvant GKS yields survival and local failure outcomes comparable to adjuvant GKS, while significantly reducing the risk of LMS. These findings support the potential clinical advantage of neoadjuvant GKS in the management of brain metastases.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Yoo J, Jung IH, Chang WS, et al. Neoadjuvant gamma knife surgery for metastatic brain tumor: clinical use and impact on leptomeningeal seeding. J Neurooncol. 2025. PMID: 41313358. doi:10.1007/s11060-025-05345-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。